-
公开(公告)号：EP2747767B1
公开(公告)日：2019-02-20
申请号：EP12828679.6
申请日：2012-08-24
Applicant: Neupharma, Inc.
Inventor： ZHU, Yong-liang , QIAN, Xiangping
IPC: A61K31/497 , C07D401/04 , C07D403/04 , C07D413/04 , C07D241/42 , C07D241/44 , A61P35/00
CPC classification number: A61K31/498 , A61K31/18 , A61K31/5377 , A61K45/06 , C07D241/42 , C07D241/44 , C07D401/04 , C07D403/04 , C07D413/04 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/5748 , G01N2333/47
Abstract: Chemical entities that are benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions and methods of treatment of cancer are described.
-
公开(公告)号：EP3413052A2
公开(公告)日：2018-12-12
申请号：EP18165873.3
申请日：2014-03-26
Applicant: Roche Diagnostics GmbH , F. Hoffmann-La Roche AG
Inventor： Karl, Johann , Wienhues-Thelen, Ursula-Henrike , Block, Dirk , Zaugg, Christian , Brunner, Hans-Peter , Januzzi, James , Ziegler, André , Braz, Julian , Dieterle, Thomas , Kaiser, Edelgard
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2800/325
Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：EP3109636B1
公开(公告)日：2018-10-31
申请号：EP15751770.7
申请日：2015-02-13
Inventor： MATSUDA, Noriyuki , KOYANO, Fumika , OKATSU, Kei , GO, Etsu , KIMURA, Mayumi , SAEKI, Yasushi
CPC classification number: G01N33/6896 , A61K38/00 , C07K14/47 , C07K16/18 , C12Q1/485 , C12Y207/11001 , G01N33/5079 , G01N2333/47 , G01N2333/912 , G01N2333/91215 , G01N2440/14 , G01N2500/00 , G01N2500/20 , G01N2800/2835
Abstract: An antibody has as a target molecule a ubiquitin protein comprising a phosphorylated serine residue at position 65. In addition, a method is provided for specifically detecting Parkinson's disease at an early stage, in which a target molecule is a ubiquitin protein comprising a phosphorylated serine residue at position 65, a pharmaceutical composition for definitively treating or preventing Parkinson's disease, and a method for screening for the pharmaceutical composition.
-
4.发明公开
公开(公告)号：EP3388078A1
公开(公告)日：2018-10-17
申请号：EP18174323.8
申请日：2016-03-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Mahr, Andrea , Stevermann, Lea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
5.发明公开
公开(公告)号：EP3388075A1
公开(公告)日：2018-10-17
申请号：EP18174251.1
申请日：2016-03-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Mahr, Andrea , Stevermann, Lea , Weinschenk, Toni , Schoor, Oliver , Fritsche, Jens , Singh, Harpreet
CPC classification number: C07K14/70539 , A61K38/00 , A61K38/06 , A61K38/08 , A61K38/1774 , A61K39/0005 , A61K39/0011 , A61K45/06 , A61K2039/5158 , A61K2039/54 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/02 , C07K7/06 , C07K14/001 , C07K14/47 , C07K14/4702 , C07K14/4748 , C07K14/7051 , C07K16/18 , C07K16/2833 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2319/00 , C07K2319/40 , C12N5/0636 , C12N5/0638 , C12N9/6491 , C12N2501/998 , C12N2502/11 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Y304/24 , G01N33/505 , G01N33/5088 , G01N33/566 , G01N33/56972 , G01N33/56977 , G01N2333/47 , G01N2333/70503 , G01N2333/7051 , G01N2333/70539 , G01N2500/10
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：EP2883052B1
公开(公告)日：2018-09-26
申请号：EP13753421.0
申请日：2013-08-12
Applicant: Instituto Superiore Di Sanita'
Inventor： LAVIOLA, Giovanni , ADRIANI, Walter , PORFIRIO, Maria Cristina , CURATOLO, Paolo , GRANSTREM, Oleg
IPC: G01N33/564 , C07K14/47
CPC classification number: G01N33/564 , C07K14/47 , G01N2333/47 , G01N2800/305 , G01N2800/50 , G01N2800/52
Abstract: Methods for detecting autoantibodies against fragments of human dopamine transporter (hDAT)- in biological fluids enable the clinical diagnosis and monitoring of the treatment of ADHD, and is capable of differentiating between ADHD and other "ADHD-like" syndromes.
-
公开(公告)号：EP2723379B1
公开(公告)日：2018-09-12
申请号：EP12802721.6
申请日：2012-06-22
Inventor： WEIHOFEN, Andreas , GRIMM, Jan , HOCK, Christoph , NITSCH, Roger , SU, Lihe , WEINREB, Paul
IPC: A61K39/395 , C07K16/18
CPC classification number: C07K16/18 , A61K47/6849 , C07K2317/34 , C07K2317/565 , G01N33/6896 , G01N2333/47 , G01N2800/28 , G01N2800/2828 , G01N2800/2835
Abstract: Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
-
公开(公告)号：EP2791673B1
公开(公告)日：2018-08-29
申请号：EP12858515.5
申请日：2012-12-14
Applicant: Afilalo, Jonathan , Meyer Ohayon, Samuel , Afilalo, Marc
Inventor： Afilalo, Jonathan , Meyer Ohayon, Samuel , Afilalo, Marc
IPC: G01N33/48 , G01N33/483 , G01N33/53 , G01N33/68
CPC classification number: G01N33/6893 , G01N33/6875 , G01N2333/47 , G01N2800/7042
Abstract: The present invention provides LMNA gene products as biomarkers for the determination of the vulnerability of an individual to an adverse health outcome when the individual is submitted to a stressor. As herewith provided, a decreased expression of a lamin A/C polypeptide, an increased expression in a lamin precursor polypeptide or a decreased ratio between the lamin A/C polypeptide/lamin precursor polypeptide is observed in individuals who are more vulnerable to an adverse health outcome upon the introduction of a stressor. In some embodiments, these susceptible individuals are considered as frail. The present application provides methods for using this biomarker to assess the risk associated thereto, commercial packages for performing the methods, software products as well as associated systems.
-
公开(公告)号：EP3363458A2
公开(公告)日：2018-08-22
申请号：EP18166281.8
申请日：2014-12-09
Applicant: TARGOVAX ASA
Inventor： ERIKSEN, Jon Amund
CPC classification number: A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/57 , A61K2039/70 , C07K14/82 , C12Q2600/156 , G01N33/483 , G01N33/505 , G01N2333/47
Abstract: There is disclosed a peptide for use as a vaccine or medicament and which corresponds to a fragment of the RAS protein. The peptide comprises a region of at least 8 amino acids which includes position 13 of the RAS protein, and said region has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. The peptide has a G13C or a G13R amino acid substitution at the amino acid corresponding to said position 13.
-
公开(公告)号：EP3357505A1
公开(公告)日：2018-08-08
申请号：EP18164079.8
申请日：2014-12-09
Applicant: TARGOVAX ASA
Inventor： ERIKSEN, Jon Amund
CPC classification number: A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/57 , A61K2039/70 , C07K14/82 , C12Q2600/156 , G01N33/483 , G01N33/505 , G01N2333/47
Abstract: There is disclosed a T-cell preparation comprising T-cells specific for a peptide when presented on an MHC molecule. The peptide corresponds to a fragment of the RAS protein and comprises a region of at least 8 amino acids which include position 12, 13 or 61 of the RAS protein. This region has at least 6 amino acid residues, other than at said position 12, 13 or 61, which are identical to the corresponding region of the RAS protein. The peptide has an amino acid substitution at the amino acid corresponding to position 12, 13 or 61 of the RAS protein.
-
-
-
-
-
-
-
-
-
Search Results
699
records
(took 0.041 seconds)
